Stockscreener 앱 받기
52.92
0.04%
0.02
시간 외 거래:
52.92
전일 마감가:
$52.90
열려 있는:
$52.88
하루 거래량:
1.47M
Relative Volume:
0.45
시가총액:
$2.76B
수익:
$190.41M
순이익/손실:
$20.48M
주가수익비율:
237.52
EPS:
0.2228
순현금흐름:
$46.66M
1주 성능:
+0.30%
1개월 성능:
+34.01%
6개월 성능:
+12.91%
1년 성능:
-30.81%
1일 변동 폭
$52.85
$52.92
1주일 범위
$52.77
$52.92
52주 변동 폭
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.92 | 2.76B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-07 | 개시 | Goldman | Buy |
| 2025-08-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine pairs $811M quarter with $2.9B Soleno deal for rare-disease drug - Stock Titan
Neurocrine Biosciences (NBIX) posts strong Q1 2026 results and plans $2.9B Soleno deal - Stock Titan
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Neurocrine in the spotlight: Can growth justify Soleno bet? By Investing.com - Investing.com UK
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - ChartMill
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of - GlobeNewswire
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
SLNO DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Soleno Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar - GlobeNewswire
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline - GlobeNewswire Inc.
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Soleno Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - Scott Coop
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - ChartMill
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Soleno Therapeutics (SLNO) price target decreased by 15.57% to 57.53 - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
Soleno Therapeutics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, ... - Caledonian Record
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - Business Wire
Soleno Therapeutics Executive Compensation, Corporate Governance, and Pay Practices 2025 - Minichart
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Pictet Asset Management Holding SA Has $28.90 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - ChartMill
Neurocrine to acquire Soleno Therapeutics (SLNO) in $53-per-share cash deal - Stock Titan
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ChartMill
SLNO Shareholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - Morningstar
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt – Company AnnouncementFT.com - Financial Times
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud - GuruFocus
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Hav - GuruFocus
SOLENO DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
[SC TO-T/A] SOLENO THERAPEUTICS INC Amended Third-Party Tender Offer | SLNO SEC FilingForm SC TO-T/A - Stock Titan
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
MSN - MSN
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):